Lv3
308 积分 2025-10-20 加入
Olverembatinib, a novel BCR-ABL tyrosine kinase inhibitor, exhibits anti-tumor activity and synergizes with gemcitabine in pancreatic ductal adenocarcinoma
7天前
已完结
CAR-X cell engineering
7天前
已完结
Phase III Data Support Chemo-Free Approach to ALL
12天前
已完结
Blinatumomab and Ponatinib Versus Hyper‐ CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis
12天前
已完结
Lisaftoclax combined with ixazomib and dexamethasone after CAR-T for maintenance therapy in transplant-ineligible relapsed/refractory ultra-high-risk multiple myeloma: two case reports and literature review
17天前
已完结
Novel Fusion Gene Transcripts and Targetable Mutations in High‐Risk B‐ ALL With Exceptional Response to Venetoclax‐Based Therapy
18天前
已完结
Efficacy and Safety of Azacitidine Combined With Lisaftoclax in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome With Increased Blasts
20天前
已完结
Effects of a High‐Fat Meal on the Pharmacokinetics of Olverembatinib in Patients With Chronic Myeloid Leukemia
21天前
已完结
Blinatumomab in pediatric acute lymphoblastic leukemia: current and future use
26天前
已完结
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial
1个月前
已完结
皖公网安备34019202002308
